95.4 USD
+0.23 (+0.24%)
INCY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. INCY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INCY may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make INCY a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year INCY was profitable.
INCY had a positive operating cash flow in the past year.
Of the past 5 years INCY 4 years were profitable.
INCY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
INCY has a Return On Assets of 18.78%. This is amongst the best in the industry. INCY outperforms 96.61% of its industry peers.
INCY has a better Return On Equity (25.55%) than 96.99% of its industry peers.
INCY has a Return On Invested Capital of 19.88%. This is amongst the best in the industry. INCY outperforms 97.74% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 18.22%.
The last Return On Invested Capital (19.88%) for INCY is above the 3 year average (7.24%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY's Profit Margin of 24.69% is amongst the best of the industry. INCY outperforms 94.73% of its industry peers.
INCY's Profit Margin has declined in the last couple of years.
INCY's Operating Margin of 26.10% is amongst the best of the industry. INCY outperforms 95.86% of its industry peers.
INCY's Operating Margin has declined in the last couple of years.
INCY's Gross Margin of 93.47% is amongst the best of the industry. INCY outperforms 94.35% of its industry peers.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INCY is creating value.
Compared to 1 year ago, INCY has less shares outstanding
Compared to 5 years ago, INCY has less shares outstanding
INCY has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 8.63 indicates that INCY is not in any danger for bankruptcy at the moment.
INCY's Altman-Z score of 8.63 is fine compared to the rest of the industry. INCY outperforms 79.47% of its industry peers.
The Debt to FCF ratio of INCY is 0.03, which is an excellent value as it means it would take INCY, only 0.03 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.03, INCY belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 8.63 |
ROIC/WACC2.26
WACC8.81%
2.3 Liquidity
INCY has a Current Ratio of 3.20. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.20, INCY is doing worse than 62.90% of the companies in the same industry.
INCY has a Quick Ratio of 3.13. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY has a Quick ratio of 3.13. This is in the lower half of the industry: INCY underperforms 61.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 575.79% over the past year.
Measured over the past years, INCY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.21% on average per year.
Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 18.09% in the last year.
The Revenue has been growing by 14.46% on average over the past years. This is quite good.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
INCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.45% yearly.
Based on estimates for the next years, INCY will show a small growth in Revenue. The Revenue will grow by 1.17% on average per year.
EPS Next Y428.71%
EPS Next 2Y147.09%
EPS Next 3Y90.86%
EPS Next 5Y28.45%
Revenue Next Year18.26%
Revenue Next 2Y14.51%
Revenue Next 3Y12.86%
Revenue Next 5Y1.17%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.86, the valuation of INCY can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 95.48% of the companies listed in the same industry.
INCY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.59.
With a Price/Forward Earnings ratio of 11.84, the valuation of INCY can be described as very reasonable.
97.55% of the companies in the same industry are more expensive than INCY, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, INCY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.86 | ||
| Fwd PE | 11.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaper than 96.05% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, INCY is valued cheaply inside the industry as 96.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.65 | ||
| EV/EBITDA | 11.36 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
INCY's earnings are expected to grow with 90.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y147.09%
EPS Next 3Y90.86%
5. Dividend
5.1 Amount
No dividends for INCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INCY (12/11/2025, 10:56:37 AM)
95.4
+0.23 (+0.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.03%
Inst Owner Change1.22%
Ins Owners1.74%
Ins Owner Change-6.67%
Market Cap18.73B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75
Price Target96.26 (0.9%)
Short Float %4.94%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)9.9%
PT rev (3m)14.6%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)6.19%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.68%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)2.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.86 | ||
| Fwd PE | 11.84 | ||
| P/S | 3.89 | ||
| P/FCF | 15.65 | ||
| P/OCF | 14.97 | ||
| P/B | 4.03 | ||
| P/tB | 4.28 | ||
| EV/EBITDA | 11.36 |
EPS(TTM)6.42
EY6.73%
EPS(NY)8.06
Fwd EY8.45%
FCF(TTM)6.1
FCFY6.39%
OCF(TTM)6.37
OCFY6.68%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.03
PEG (5Y)N/A
Graham Number58.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 8.63 |
F-Score7
WACC8.81%
ROIC/WACC2.26
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y147.09%
EPS Next 3Y90.86%
EPS Next 5Y28.45%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.26%
Revenue Next 2Y14.51%
Revenue Next 3Y12.86%
Revenue Next 5Y1.17%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 7 / 10 to INCY.
What is the valuation status for INCY stock?
ChartMill assigns a valuation rating of 9 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
What is the valuation of INCYTE CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for INCYTE CORP (INCY) is 14.86 and the Price/Book (PB) ratio is 4.03.
What is the earnings growth outlook for INCYTE CORP?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.